Poxel Aktie [WKN DE: A14M04 / ISIN: FR0012432516]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Poxel SA

27.12.17		Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
02.11.17		Poxel Announces Participation at the Jefferies 2017 London Healthcare Conference (Businesswire)
16.10.17		Poxel Announces Third Quarter 2017 Financial Update (Businesswire)
21.09.17		Poxel Reports Results for the First Half 2017 and Provides Corporate Update (Businesswire)
20.09.17		Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial (Businesswire)
14.09.17		Poxel Presents Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting (Businesswire)
06.09.17		Poxel to Present Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting (Businesswire)
28.08.17		Poxel Presents New Preclinical Imeglimin Data Demonstrating Improvement of Both Peripheral and Coronary Vascular Function at the European Society of Cardiology Congress (Businesswire)
10.07.17		Poxel Announces Second Quarter 2017 Financial Update (Businesswire)
06.06.17		Poxel Announces Additional Positive Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes (Businesswire)
22.05.17		Poxel Presents Imeglimin Japanese Phase 1 Results and Mechanistic Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan (Businesswire)
03.04.17		Poxel Reports Results for Fiscal Year 2016 and Provides Corporate Update (Businesswire)
07.03.17		Poxel Announces Appointment of Christophe Arbet-Engels, MD, PhD, MBA, as Chief Medical Officer and EVP Late Development & Medical Affairs, Based in Boston (Businesswire)
27.01.17		Poxel Announces Fourth Quarter 2016 Financial Update (Businesswire)
22.12.16		Poxel Announces CFO Departure (Businesswire)
21.11.16		Poxel to Present New Imeglimin Data Demonstrating Beta Cell Function Preservation at the 14th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Businesswire)
14.11.16		Poxel Joins Organizations Worldwide to Recognize World Diabetes Day (Businesswire)
09.11.16		Poxel Announces Participation in Two Upcoming Investor Conferences (Businesswire)
21.10.16		Poxel Announces Third Quarter 2016 Financial Results and Corporate Update (Businesswire)
15.09.16		Poxel Presents New Data on Imeglimin and PXL770 at the European Association for the Study of Diabetes Annual Meeting (Businesswire)
12.09.16		Poxel Reports Results for First Half 2016 and Provides Corporate Update (Businesswire)
06.09.16		Poxel to Present New Imeglimin and PXL770 Data at the 52nd European Association for the Study of Diabetes Annual Meeting (Businesswire)
26.07.16		Poxel Announces Publication of Important New Mechanism Data for Imeglimin Relating to Insulin Secretion in the Treatment of Type 2 Diabetes (Businesswire)
18.07.16		Poxel Closes a €26.5 Million Capital Increase (Businesswire)
12.07.16		Poxel Provides 1H16 Cash and Turnover Figures (Businesswire)
30.06.16		Poxel Announces Patient Enrollment Completed for Imeglimin Phase 2b Clinical Trial in Type 2 Diabetes in Japan (Businesswire)
20.06.16		Poxel Announces Positive Results From the First Stage of the Ongoing PXL770 Phase 1 Trial (Businesswire)
14.06.16		Poxel Makes Available to the Public Its 2015 Reference Document (Businesswire)
13.06.16		Poxel Presents New Data on Imeglimin’s Dual Mechanism of Action at the American Diabetes Association’s 76th Scientific Sessions (Businesswire)
05.05.16		Poxel Provides 1Q16 Cash Figures (Businesswire)
04.05.16		Poxel Plans to Conduct Registered Initial Public Offering in the United States (Businesswire)
18.04.16		Poxel Announces Election of Pierre Legault as Chairman of the Board of Directors (Businesswire)
01.04.16		Poxel Reports Results for Fiscal Year 2015 and Provides Corporate Update (Businesswire)
29.03.16		Poxel has been Granted U.S. Composition of Matter Patent for Direct AMPK Activator PXL770 for the Potential Treatment of Type 2 Diabetes and Related Disorders (Businesswire)
14.03.16		Poxel Appoints Jonae R. Barnes as Senior Vice President Investor Relations and Public Relations, Based in Boston (Businesswire)
04.03.16		Poxel to Present at 28th Annual ROTH Conference (Businesswire)
01.02.16		Poxel Appoints Janice Bourque and Pierre Legault to its Board of Directors (Businesswire)
28.01.16		Poxel Provides YE15 Cash and Turnover Figures (Businesswire)
04.01.16		Poxel Announces its 2016 Financial Calendar (Businesswire)
14.12.15		Poxel Announces Imeglimin Phase 2b Initiation in Japan (Businesswire)
23.11.15		Poxel Presents New Data on Imeglimin and PXL770 at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases in Los Angeles (Businesswire)
17.11.15		POXEL Announces Patent Access Agreement with ENYO (Businesswire)
17.11.15		POXEL Announces Patent Access Agreement with ENYO (Businesswire)
02.11.15		Imeglimin’s Innovative Mitochondria-Targeted Mechanism of Action Recognized by the Scientific Committee of the World Mitochondria Society (Businesswire)
30.10.15		Unique Mitochondria-targeting Mechanism of Action Confirmed for Poxel’s Oral Agent Imeglimin (Businesswire)
22.10.15		Poxel Reports Cash Position, Financial Results for the Third Quarter 2015 and Provides Corporate Update (Businesswire)
22.10.15		Poxel Reports Cash Position, Financial Results for the Third Quarter 2015 and Provides Corporate Update (Businesswire)
07.10.15		Poxel Announces Upcoming Presentations on New Imeglimin Data at Two Key Scientific Conferences (Businesswire)
31.08.15		Poxel Reports Financial Results and Corporate Update for the First Half of 2015 (Businesswire)
24.07.15		POXEL beschafft 20 Millionen Euro durch Privatplatzierung bei führenden Healthcare-Investoren aus den USA (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Crash oder Rally: Das sind die Experten-Prognosen für Kryptowährungen wie Bitcoin, Ethereum & Co. im Jahr 2025

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

S&P 500-Papier Tesla-Aktie: So viel hätte eine Investition in Tesla von vor 5 Jahren abgeworfen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.12.2024 23:10
Kaufwert:	EUR
	Hinzufügen Speichern